Utah Medical Products Inc

Utah Medical Products Inc(UTMD)股票分析

$71.640

-0.122 (-0.17%)收盘时

Loading chart…
High
72.500
Open
71.920
VWAP
71.92
Vol
31.09K
Mkt Cap
235.88M
Low
71.630
Amount
2.24M
EV/EBITDA, TTM
0.00

Utah Medical Products, Inc. manufactures and markets a range of specialty medical devices. The Company’s range of products includes those used in critical care areas and the labor and delivery departments of hospitals, as well as outpatient clinics and physicians offices. Its products are sold directly to end-user facilities in the United States, Ireland, United Kingdom, Canada, France and Australia, and through third party distributors in other outside the United States (OUS) markets. It offers fetal monitoring accessories. Its specialized labour and delivery tools include BT-Cath, CVX-Ripe, AROM-COT, MUC-X, and Cordguard. The Company’s vacuum-assisted delivery (VAD) systems include CMI soft silicone bell-shaped birthing cups and reusable hand-held vacuum pumps, which are the safest products available for use in vacuum-assisted operative deliveries. Its neonatal intensive care products include Disposa-Hood and GESCO. It also distributes harm-reduction medical devices.

AI analysis of Utah Medical Products Inc (UTMD)

buy

Utah Medical Products Inc is a good buy right now due to its current price of $72.77, which is supported by a solid forward P/E ratio of 13.04, indicating attractive valuation compared to future earnings. Additionally, the company has shown a year-to-date change of +28.80%, reflecting strong momentum. However, a risk to consider is the recent revenue decline of 10.2% year-over-year, which could impact future performance.

估值指标

The current forward P/E ratio for Utah Medical Products Inc (UTMD) is 13.04, compared to its 5-year average forward P/E of 1.76.

Forward P/E

Strongly Overvalued
5Y Average P/E
1.76
Current P/E
13.04
高估
6.22
低估
-2.71

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for UTMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%UTMD

$61.55

情景价格

B

Base

Base · 50%UTMD

$52.40

情景价格

B

Bear

Bear · 25%UTMD

$44.83

情景价格

事件时间线

2026-08-31 (ET)

09:30:00

Femcare Acquires Orion Medical Supplies in the UK

2026-07-23 (ET)

09:30:00

Company Reports Q2 Revenue of $8.5M

2026-04-23 (ET)

09:10:00

Q1 Revenue Reports $8.72M vs. $9.71M Last Year

2026-01-29 (ET)

09:10:00

Company Reports Q4 Revenue of $9.04M

2025-11-04 (ET)

10:06:12

Utah Medical Products Increases Quarterly Cash Dividend by 1.6% to $0.31 per Share

资讯

UTMD FAQ — answered by Alphio AI

Utah Medical Products, Inc. manufactures and markets a range of specialty medical devices. The Company’s range of products includes those used in critical care areas and the labor and delivery departments of hospitals, as well as outpatient clinics and physicians offices. Its products are sold directly to end-user facilities in the United States, Ireland, United Kingdom, Canada, France and Australia, and through third party distributors in other outside the United States (OUS) markets. It offers fetal monitoring accessories. Its specialized labour and delivery tools include BT-Cath, CVX-Ripe, AROM-COT, MUC-X, and Cordguard. The Company’s vacuum-assisted delivery (VAD) systems include CMI soft silicone bell-shaped birthing cups and reusable hand-held vacuum pumps, which are the safest products available for use in vacuum-assisted operative deliveries. Its neonatal intensive care products include Disposa-Hood and GESCO. It also distributes harm-reduction medical devices. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Utah Medical Products Inc is a good buy right now due to its current price of $72.77, which is supported by a solid forward P/E ratio of 13.04, indicating attractive valuation compared to future earnings. Additionally, the company has shown a year-to-date change of +28.80%, reflecting strong momentum. However, a risk to consider is the recent revenue decline of 10.2% year-over-year, which could impact future performance.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始